Literature DB >> 23651743

Isoniazid preventive treatment: predictors of adverse events and treatment completion.

L R Codecasa1, N Murgia, M Ferrarese, M Delmastro, A C Repossi, L Casali, G Besozzi, G Ferrara, M C Raviglione.   

Abstract

SETTING: Villa Marelli Institute (VMI), Niguarda Ca'Granda Hospital, Milan, Italy.
BACKGROUND: A recent report on the fatal side effects of isoniazid preventive therapy (IPT) from the United States has re-ignited discussion on the safety of this intervention.
OBJECTIVE: To evaluate IPT feasibility, treatment completion and adverse events (AE) and their determinants under field conditions.
METHODS: Data from consecutive subjects undergoing IPT at the VMI were recorded in an electronic database from 1992 to 2009. Logistic regression analysis was performed to detect completion and AE determinants.
RESULTS: A total of 11,963 patients were included in the study. AE (odds ratio [OR] 2.70, 95%CI 2.22-3.28) and human immunodeficiency virus positive status (OR 5.20, 95%CI 2.10-12.93) were the main determinants of treatment interruption among Italians, while social weakness (no housing/job; OR 2.88, 95%CI 2.43-3.42), AEs (OR 1.33, 95%CI 1.15-1.53, 2.22-3.28) and screening in undocumented subjects (OR 1.20, 95%CI 1.01-1.44) prevailed among foreigners. Age was the main determinant of transaminase increase (OR 1.03, 95%CI 1.03-1.04), as were AEs of the gastrointestinal (OR 1.02, 95%CI 1.02-1.03), central nervous (OR 1.02, 95%CI 1.02-1.05) and peripheral nervous systems (OR 1.04, 95%CI 1.02-1.05).
CONCLUSION: This analysis demonstrates the feasibility and safety of IPT, with determinants of interruption and AEs being predictable and addressable.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23651743     DOI: 10.5588/ijtld.12.0677

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  "It's about my life": facilitators of and barriers to isoniazid preventive therapy completion among people living with HIV in rural South Africa.

Authors:  Karen B Jacobson; Linda Niccolai; Nonhle Mtungwa; Anthony P Moll; Sheela V Shenoi
Journal:  AIDS Care       Date:  2017-02-01

Review 2.  Systematic review of risk factors for nonadherence to TB treatment in immigrant populations.

Authors:  Stephanie Lin; G J Melendez-Torres
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-05       Impact factor: 2.184

3.  Assessment of national tuberculosis and HIV collaborative program implementation status in health care settings of Ethiopia.

Authors:  Wudinesh Belete; Minilik Demissie; Atsbeha Gebreegziabher; Desta Kassa; Gebremedine Gebre-Michael; Getnet Mesfin; Abebaw Kebede; Andargachew Kumsa; Lelissa Fekadu; Biruk Kebede; Fekadeselassie Mikru; Kassa Hailu; Addisalem Yilma; Eshetu Kebede; Ismael Hassen; Abera Bekele; Getachew Wondimagegne; Kumlachew Abate; Daniel Fiseha; Ezra Shimeles; Yibeltal Assefa
Journal:  Ethiop J Public Health Nutr       Date:  2017

4.  Factors associated with noncompletion of latent tuberculosis infection treatment in an inner-city population in Edmonton, Alberta.

Authors:  Kathy Malejczyk; Jennifer Gratrix; Avril Beckon; Danusia Moreau; Gwenna Williams; Dennis Kunimoto; Rabia Ahmed
Journal:  Can J Infect Dis Med Microbiol       Date:  2014-09       Impact factor: 2.471

5.  Evaluation of the uptake of tuberculosis preventative therapy for people living with HIV in Namibia: a multiple methods analysis.

Authors:  Clay Roscoe; Chris Lockhart; Michael de Klerk; Andrew Baughman; Simon Agolory; Michael Gawanab; Heather Menzies; Anna Jonas; Natanael Salomo; Negussie Taffa; David Lowrance; Katherine Robsky; Deanna Tollefson; Eric Pevzner; Ndapewa Hamunime; Farai Mavhunga; Helena Mungunda
Journal:  BMC Public Health       Date:  2020-12-01       Impact factor: 3.295

Review 6.  Interventions for improving adherence to treatment for latent tuberculosis infection: a systematic review.

Authors:  Anke L Stuurman; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anouk M Oordt-Speets; Andreas Sandgren; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-06-08       Impact factor: 3.090

7.  Initiation and completion rates for latent tuberculosis infection treatment: a systematic review.

Authors:  Andreas Sandgren; Marije Vonk Noordegraaf-Schouten; Femke van Kessel; Anke Stuurman; Anouk Oordt-Speets; Marieke J van der Werf
Journal:  BMC Infect Dis       Date:  2016-05-17       Impact factor: 3.090

8.  Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy.

Authors:  Simone Villa; Maurizio Ferrarese; Giovanni Sotgiu; Paola Francesca Castellotti; Laura Saderi; Cecilia Grecchi; Matteo Saporiti; Mario Raviglione; Luigi Ruffo Codecasa
Journal:  J Clin Med       Date:  2019-12-31       Impact factor: 4.241

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.